AU2002318175B2 - Compositions and methods for treating hyperimmune response in the eye - Google Patents

Compositions and methods for treating hyperimmune response in the eye Download PDF

Info

Publication number
AU2002318175B2
AU2002318175B2 AU2002318175A AU2002318175A AU2002318175B2 AU 2002318175 B2 AU2002318175 B2 AU 2002318175B2 AU 2002318175 A AU2002318175 A AU 2002318175A AU 2002318175 A AU2002318175 A AU 2002318175A AU 2002318175 B2 AU2002318175 B2 AU 2002318175B2
Authority
AU
Australia
Prior art keywords
antibody
eye
antibodies
gamma
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002318175A
Other languages
English (en)
Other versions
AU2002318175A1 (en
Inventor
Boris Skurkovich
Simon Skurkovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Biotherapy Concepts Inc
Original Assignee
Advanced Biotherapy Concepts Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biotherapy Concepts Inc filed Critical Advanced Biotherapy Concepts Inc
Publication of AU2002318175A1 publication Critical patent/AU2002318175A1/en
Application granted granted Critical
Publication of AU2002318175B2 publication Critical patent/AU2002318175B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2002318175A 2001-06-05 2002-06-04 Compositions and methods for treating hyperimmune response in the eye Ceased AU2002318175B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29589501P 2001-06-05 2001-06-05
US60/295,895 2001-06-05
US09/894,287 2001-06-28
US09/894,287 US6534059B2 (en) 2001-06-05 2001-06-28 Compositions and methods for treating hyperimmune response in the eye
PCT/US2002/017677 WO2002098460A1 (en) 2001-06-05 2002-06-04 Compositions and methods for treating hyperimmune response in the eye

Publications (2)

Publication Number Publication Date
AU2002318175A1 AU2002318175A1 (en) 2003-05-08
AU2002318175B2 true AU2002318175B2 (en) 2006-01-05

Family

ID=26969391

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002318175A Ceased AU2002318175B2 (en) 2001-06-05 2002-06-04 Compositions and methods for treating hyperimmune response in the eye

Country Status (8)

Country Link
US (2) US6534059B2 (enExample)
EP (1) EP1401496B1 (enExample)
JP (1) JP2004532885A (enExample)
AT (1) ATE343398T1 (enExample)
AU (1) AU2002318175B2 (enExample)
CA (1) CA2449488C (enExample)
DE (1) DE60215649D1 (enExample)
WO (1) WO2002098460A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6709655B2 (en) * 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6534059B2 (en) * 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6712976B2 (en) * 2001-09-13 2004-03-30 Abtech Industries, Inc. Dual-action decontamination system
US7335759B2 (en) 2002-12-02 2008-02-26 Universidad Nacional Autónoma de Méxica (UNAM) Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
MXPA06000965A (es) * 2003-07-25 2007-05-04 Silanes Sa De Cv Lab Administracion de fragmentos f(ab??)2 de anticuerpos anti-citocinas.
MX2007008719A (es) 2005-01-27 2007-09-11 Novimmune Sa Anticuerpos anti-interferon gamma y metodos de uso de los mismos.
US20100003264A1 (en) * 2005-03-24 2010-01-07 Washington University Reduction of Ophthalmalogic Neovascularization
US7381802B2 (en) * 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
CN101489569A (zh) * 2006-06-12 2009-07-22 席拉坎有限责任公司 眼表面疾病的局部治疗
WO2010019839A1 (en) * 2008-08-15 2010-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for using interferon gamma to absorb fluid from the subretinal space
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
JP2018515493A (ja) 2015-05-07 2018-06-14 ノビミューン エスアー Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010707A1 (en) * 1989-03-09 1990-09-20 Margreet Jonker Pharmaceutical product for the treatment of immunoregulatory disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
JP2523562B2 (ja) 1985-10-25 1996-08-14 ザイモジェネティックス インコーポレーテッド 外来タンパク質を分泌することを目的としたｂａｒ１の使用法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU2777092A (en) * 1991-10-04 1993-05-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Treatment of ocular inflammation by blockage of cell adhesion molecules
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
DE19535073C1 (de) * 1995-09-21 1997-02-20 Roland Dr Grosmann Verfahren zur künstlichen Inkubation von Hühnereiern
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6534059B2 (en) * 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010707A1 (en) * 1989-03-09 1990-09-20 Margreet Jonker Pharmaceutical product for the treatment of immunoregulatory disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Skurkovich et al., Medical Hypothesis 41:177-185 1993 *
Yamagami et al., Transplantation 67:600-604 1999 *

Also Published As

Publication number Publication date
JP2004532885A (ja) 2004-10-28
US20020182212A1 (en) 2002-12-05
EP1401496A1 (en) 2004-03-31
US20030224005A1 (en) 2003-12-04
US6534059B2 (en) 2003-03-18
DE60215649D1 (de) 2006-12-07
EP1401496A4 (en) 2005-08-31
WO2002098460A1 (en) 2002-12-12
ATE343398T1 (de) 2006-11-15
HK1063601A1 (en) 2005-01-07
CA2449488A1 (en) 2002-12-12
US7232568B2 (en) 2007-06-19
EP1401496B1 (en) 2006-10-25
CA2449488C (en) 2010-02-09

Similar Documents

Publication Publication Date Title
US6534059B2 (en) Compositions and methods for treating hyperimmune response in the eye
CA2637917C (en) Therapeutic agents for diseases involving choroidal neovascularization
EP0831906B1 (en) Treatment of t cell mediated autoimmune disorders
AU2002318175A1 (en) Compositions and methods for treating hyperimmune response in the eye
WO2009014263A1 (ja) インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
KR20170141692A (ko) 안구 장애를 치료하기 위한 아디포넥틴 펩티드모방체
EP1004312A1 (en) Method for treating multiple sclerosis
US20040086508A1 (en) Treatment of organ transplant rejection
US6861056B2 (en) Compositions and methods for treating hyperimmune response in the eye
DE69736244T2 (de) Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
JP2020535167A (ja) 抗ｐａｃａｐ抗体
HU211059B (en) Method for producing pharmaceutical compositions usable for reducing immunglobulin e responses, containing human il-4 antibodies
MX2012002768A (es) Anticuerpos humanizados para peptido-6 derivado de hsp65, metodos y usos de los mismos.
US20040062768A1 (en) Compositions and methods for treating hyperimmune response in the eye
JPH08506325A (ja) サイトメガロウイルスに対するヒトモノクローナル抗体
HK1063601B (en) Compositions and methods for treating hyperimmune response in the eye
US20050152902A1 (en) Treatment of diabetic retinopathy
CN114901313A (zh) 急性期的视神经脊髓炎的预防或治疗剂
AU2022243562A1 (en) Humanized mab107
WO2003007874A2 (en) Anti-tumor activity from reptile serum
HK40116467A (en) Use of anti-ox40 antibodies in the treatment of inflammatory or immune diseases
JP2528549B2 (ja) ヒトｉｌ―２レセプタ―重鎖に結合する新規モノクロ―ナル抗体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired